Literature DB >> 27600436

In vitro cytogenetic evaluation of the particular combination of flurbiprofen and roxithromycin.

Taygun Timocin1, Mehmet Tahir Husunet1, Ebrahim Valipour2, Mostafa Norizadeh Tazehkand3, Rima Celik1, Mehmet Topaktas4, Hasan B Ila4.   

Abstract

Flurbiprofen (FLB) (anti-inflammatory and analgesic drug) and roxithromycin (RXM) (antibiotic) were widely used in world wide. This study deals with investigation of genotoxicity, cytotoxicity, and oxidative stress effects of a particular combination of these drugs in human cultured lymphocytes. Also, DNA damaging-protective effects of combination of these drugs were analyzed on plasmid DNA. Human lymphocytes were treated with different concentrations (FLB + RXM; 10 μg/mL + 25 μg/mL, 15 μg/mL + 50 μg/mL, and 20 μg/mL + 100 μg/mL) of the drugs following by study of their genotoxic and cytotoxic effects by analysis of cytokinesis-block micronucleus test and nuclear division index, respectively. The effect of the combination in aspect of anti-oxidative and DNA damaging activity was evaluated on Pet-22b plasmid. According to our results, the combination of FLB and RXM did not show a notable genotoxic effect on cells. Although each of the substances had been shown as a cytotoxic agent by previous researchers, in this research, the combination of these drugs did not exhibit any adverse effect on cell division. FLB had DNA protection effect against H2O2 while in combination with RXM had not the same effect on the plasmid.

Entities:  

Keywords:  Flurbiprofen; Roxithromycin; cytotoxicity; genotoxicity; micronucleus; oxidative stress

Mesh:

Substances:

Year:  2016        PMID: 27600436     DOI: 10.1080/01480545.2016.1223097

Source DB:  PubMed          Journal:  Drug Chem Toxicol        ISSN: 0148-0545            Impact factor:   3.356


  1 in total

1.  In vitro cytogenotoxic evaluation of sertraline.

Authors:  Erman Salih Istifli; Rima Çelik; Mehmet Tahir Hüsunet; Nesrin Çetinel; Osman Demirhan; Hasan Basri Ila
Journal:  Interdiscip Toxicol       Date:  2019-10-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.